Arbutus Biopharma Corporation (FRA:I9DN)

Arbutus Biopharma Statistics

Total Valuation

FRA:I9DN has a market cap or net worth of EUR 731.44 million. The enterprise value is 654.61 million.

Market Cap	731.44M
Enterprise Value	654.61M

Important Dates

The next estimated earnings date is Thursday, March 5, 2026.

Earnings Date	Mar 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	192.32M
Shares Outstanding	n/a
Shares Change (YoY)	+5.88%
Shares Change (QoQ)	-0.32%
Owned by Insiders (%)	1.57%
Owned by Institutions (%)	48.87%
Float	126.13M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	58.76
PB Ratio	11.09
P/TBV Ratio	11.09
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-18.17
EV / Sales	51.97
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-16.93

Financial Position

The company has a current ratio of 18.80, with a Debt / Equity ratio of 0.06.

Current Ratio	18.80
Quick Ratio	18.31
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	-0.10
Interest Coverage	-287.66

Financial Efficiency

Return on equity (ROE) is -45.88% and return on invested capital (ROIC) is -20.03%.

Return on Equity (ROE)	-45.88%
Return on Assets (ROA)	-16.46%
Return on Invested Capital (ROIC)	-20.03%
Return on Capital Employed (ROCE)	-33.89%
Revenue Per Employee	282,925
Profits Per Employee	-818,925
Employee Count	44
Asset Turnover	0.12
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +15.07% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+15.07%
50-Day Moving Average	3.77
200-Day Moving Average	3.17
Relative Strength Index (RSI)	49.13
Average Volume (20 Days)	384

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.80

Income Statement

In the last 12 months, FRA:I9DN had revenue of EUR 12.45 million and -36.03 million in losses. Loss per share was -0.19.

Revenue	12.45M
Gross Profit	-12.31M
Operating Income	-26.72M
Pretax Income	-36.03M
Net Income	-36.03M
EBITDA	-26.14M
EBIT	-26.72M
Loss Per Share	-0.19

Balance Sheet

The company has 79.86 million in cash and 3.93 million in debt, giving a net cash position of 75.94 million.

Cash & Cash Equivalents	79.86M
Total Debt	3.93M
Net Cash	75.94M
Net Cash Per Share	n/a
Equity (Book Value)	65.97M
Book Value Per Share	0.34
Working Capital	78.63M

Cash Flow

In the last 12 months, operating cash flow was -38.59 million and capital expenditures -73,298, giving a free cash flow of -38.66 million.

Operating Cash Flow	-38.59M
Capital Expenditures	-73,298
Free Cash Flow	-38.66M
FCF Per Share	n/a

Margins

Gross margin is -98.86%, with operating and profit margins of -214.67% and -289.45%.

Gross Margin	-98.86%
Operating Margin	-214.67%
Pretax Margin	-289.45%
Profit Margin	-289.45%
EBITDA Margin	-209.98%
EBIT Margin	-214.67%
FCF Margin	n/a

Dividends & Yields

FRA:I9DN does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.88%
Shareholder Yield	-5.88%
Earnings Yield	-4.93%
FCF Yield	-5.29%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:I9DN has an Altman Z-Score of 0.23 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.23
Piotroski F-Score	4